KUALA LUMPUR: Bintai Kinden Corporation Bhd’s partner Generex Biotechnology Corporation has filed for a trademark for its li-Key vaccine and patent for its Ii-Key-SARS-CoV-2 vaccine.
In a statement issued on Thursday, Bintai Kinden said the Ii-Key vaccine was designed to be a complete vaccine for the Covid-19.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.